171569-42-9

Basic information

• Product Name: 3-Chloro-4-(hydroxyMethyl)phenol
• Synonyms: 3-Chloro-4-(hydroxyMethyl)phenol;BENZENEMETHANOL,2-CHLORO-4-HYDROXY;2-Chloro-4-hydroxybenzenemethanol;3-Chloro-4-(hydroxymethyl)
• CAS NO: 171569-42-9
• Molecular Formula: C₇H₇ClO₂
• Molecular Weight: 158.58228
• Mol File: 171569-42-9.mol

Chemical Properties

• Boiling Point: 314.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.395±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.78±0.18(Predicted)
• CAS DataBase Reference: 3-Chloro-4-(hydroxyMethyl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-4-(hydroxyMethyl)phenol(171569-42-9)
• EPA Substance Registry System: 3-Chloro-4-(hydroxyMethyl)phenol(171569-42-9)

Safety Data

• Hazardous Substances Data: 171569-42-9(Hazardous Substances Data)

Usage

Uses

Used in Personal Care Products:
3-Chloro-4-(hydroxyMethyl)phenol is used as an antiseptic and disinfectant in personal care products such as soaps, lotions, and hand sanitizers for its ability to effectively eliminate bacteria and other microorganisms, promoting hygiene and preventing the spread of infections.
Used in Medical Settings:
In the medical industry, 3-Chloro-4-(hydroxyMethyl)phenol is used as a surgical scrub to ensure a sterile environment during surgical procedures. Its antimicrobial properties help reduce the risk of postoperative infections and promote faster healing.
Used as a Preservative in Pharmaceutical Products:
3-Chloro-4-(hydroxyMethyl)phenol is used as a preservative in pharmaceutical products to prevent the growth of microorganisms and maintain the stability and efficacy of the medication. Its broad-spectrum antimicrobial activity ensures the safety and quality of pharmaceutical products.
However, it is important to note that excessive exposure to 3-Chloro-4-(hydroxyMethyl)phenol can cause skin irritation and allergic reactions in some individuals. Therefore, it should be used with caution and in accordance with safety guidelines to minimize potential adverse effects.

Upstream product

• 50-00-0 formaldehyd 
• 108-43-0 3-monochlorophenol 
• 104253-44-3 methyl 2-chloro-4-hydroxy-benzoate 
• 56363-84-9 2-chloro-4-hydroxybenzoic acid 

Downstream Products

• 1472067-93-8 3-chloro-4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate 
• 1472068-04-4 4-[(2-chloro-4-hydroxybenzyl)(4H-1,2,4-triazol-4-yl)amino]benzonitrile 
• 1182253-94-6 3-chloro-4-(chloromethyl)phenol 
• 219764-60-0 {2-chloro-4-[(phenylmethyl)oxy]phenyl}methanol 
• 213548-44-8 2'-O-(1-{2-chloro-4-[2-(4-nitrophenyl)ethoxycarbonyloxy]benzyloxy}ethyl)-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine 
• 213548-45-9 2'-O-[1-(2-chloro-4-hydroxybenzyloxy)ethyl]-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine 
• 213547-95-6 2-Chloro-4-[2-(4-nitrophenyl)ethoxycarbonyloxy]benzyl vinyl ether 
• 213549-11-2 2-chloro-4-[2-(4-nitrophenyl)ethoxycarbonyloxy]benzyl alcohol 

Relevant articles and documents

TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

Acetals as New 2′-O-Protecting Functions for the Synthesis of Oligoribonucleotides: Synthesis of Uridine Building Blocks and Evaluation of Their Relative Acid Stability

A broad variety of new acyclic vinyl ethers (see 6-41) have been synthesized via the vinyl-interchange reaction of ethyl vinyl ether at room temperature using mercury(II) trifluoroacetate as a highly efficient catalyst. The appropriate vinyl ethers were r

Solid-phase synthesis of oligoribonucleotides

A process for the preparation of oligoribonucleotides of the formula STR1 in which n, L, BB, W, T, Y', U, C1 and C2 are as defined in the description, by solid-phase synthesis is described, as are intermediates of the oligoribonucleo